MetaCap

Guardant Health (GH) vs Humana (HUM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Humana (HUM) has outperformed Guardant Health (GH) over the past year, gaining 71.7% versus a gain of 38.3%. Over five years, GH leads with a +36.4% price change compared with -9.0% for HUM. Humana is the larger company by market cap ($46.84 billion vs $19.73 billion), about 2.4 times the size, while Guardant Health is growing revenue faster (+32.9% vs +10.1%).

Humana pays a dividend yielding 0.91%, while Guardant Health does not currently pay one. Humana converts more of its revenue into profit, with a net margin of 0.9% versus -42.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GH+38.33%HUM+71.73%
+110%+38%-34%
Nov 21, 20251 yearNov 20, 2026
GH+49.45%HUM-10.32%
+92%+0%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GH versus HUM key metrics
MetricGHHUM
Share price$145.83$390.00
Market cap$19.73B$46.84B
1-day change+0.16%+2.63%
YTD return+42.77%+52.27%
1-year return+38.33%+71.73%
5-year return+36.39%-8.98%
P/E ratio (TTM)—38.05
Forward P/E—21.06
EPS (TTM)$-3.68$10.25
Dividend yield0.00%0.91%
Annual dividend$0.00$3.54
Revenue (latest FY)$982.02M$129.66B
Revenue growth (YoY)+32.88%+10.11%
Net income (latest FY)$-416.28M$1.19B
Gross margin64.46%—
Operating margin-44.53%2.09%
Net margin-42.39%0.92%
52-week high$191.05$462.87
52-week low$74.55$163.11
Distance from 52-week high-23.67%-15.74%
Analyst consensusstrong_buybuy
Avg. price target upside+37.67%+30.98%
Average volume1.97M1.46M
Shares outstanding135.29M120.10M
Employees2,49067,060
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Humana is about 2.4 times larger than Guardant Health by market value ($46.84B vs $19.73B).
  • HUM has outperformed GH by 33.4 percentage points over the past year.
  • Humana is more profitable, keeping 0.9 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
  • Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +10.11%).

About Guardant Health

GH stock →

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.

Health Care · Medical Specialities · 2,490 employees

About Humana

HUM stock →

Humana Inc. provides medical and specialty insurance products in the United States.

Health Care · Medical Specialities · 67,060 employees

GH vs HUM FAQ

Which is bigger, Guardant Health or Humana?

Humana (HUM) is larger, with a market capitalization of $46.84B compared with $19.73B for Guardant Health (GH).

Which stock has performed better over the past year, GH or HUM?

HUM returned +71.73% over the past 12 months, compared with +38.33% for GH (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Guardant Health or Humana?

Humana pays a dividend yielding 0.91%, while Guardant Health does not currently pay a regular dividend.

Are Guardant Health and Humana in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons